Please login to the form below

Not currently logged in
Email:
Password:

VBP

This page shows the latest VBP news and features for those working in and with pharma, biotech and healthcare.

Cancer Drugs Fund overhaul promises faster access to drugs

Cancer Drugs Fund overhaul promises faster access to drugs

always meant to be a stop-gap measure while the UK developed a value-based pricing (VBP) scheme for medicines. ... The failure of the VBP initiative has meant that the CDF has extended much longer than originally anticipated and it has careened over

Latest news

More from news
Approximately 8 fully matching, plus 38 partially matching documents found.

Latest Intelligence

  • The death of the cancer drugs fund? The death of the cancer drugs fund?

    of a new drug pricing system, known as value-based pricing (VBP). ... VBP however failed to be approved and the issues around access from 2010 remain today; politically it has also proved difficult for the government to remove this Fund as it has

  • UK market access: The importance of a local value story UK market access: The importance of a local value story

    Finally, there is the spectre of a new drug pricing policy in the guise of value-based pricing (VBP) that is due to come into effect at the start of 2014. ... With VBP, though still an unknown quantity for pharma and, perhaps just as worryingly, the

  • Interview: David Haslam, NICE Interview: David Haslam, NICE

    Little is known about what this will entail, however, although it has been confirmed that NICE will take primary responsibility for assessing medicines in this new VBP system. “ ... It's unclear what the impact of VBP will have on this authority, but

  • Interview: Cesar Rodriguez, Janssen Interview: Cesar Rodriguez, Janssen

    We are concerned about the implications of the value-based pricing (VBP) system of reimbursement that the government wants to implement from 2014, because as an investor, one of the things

  • The true meaning of market access? The true meaning of market access?

    For example, the UK plans to introduce Value-based Pricing (VBP) for NCEs in 2014, based on a range of cost-effectiveness thresholds, which in turn are based on disease burden, ... We need'parametric' VBP, variable over time. However, there is little

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics